Finasteride / Hydrocortisone / Latanoprost / Minoxidil / Tretinoin

(FHLMT for Men) Solution

0.3% / 1% / 0.05% / 6.5% / 0.01%

Ready to prescribe?
Disclaimer: Images are for reference only; actual products may vary.

Product Overview

This combination has been formulated as a topical preparation intended to address hair thinning and hair loss. Each component has a distinct mechanism of action related to hair development and follicular processes.

Finasteride Description1-3

Finasteride is a 5-alpha reductase inhibitor that has been shown to be beneficial in patients with symptomatic benign prostatic hyperplasia, a condition commonly affecting men over the age of 50. Finasteride has also been studied in relation to androgenetic alopecia, also known as male pattern hair loss.

Hydrocortisone4,5

Hydrocortisone is a synthetic form of cortisol, a hormone produced by the adrenal glands, and exhibits both glucocorticoid and mineralocorticoid activity. When applied topically, hydrocortisone demonstrates anti-inflammatory, antipruritic, anti-mitotic, and immunosuppressive effects. Among topical corticosteroids, hydrocortisone is classified as a low-potency option.

Latanoprost6-10

Latanoprost is an analogue of prostaglandin F2α (PGF2α) and is primarily indicated for the treatment of open-angle glaucoma and ocular hypertension. Observations have noted its association with hair growth, particularly in conditions such as androgenetic alopecia and eyelash or eyebrow hypotrichosis. Interest in its role in hair regrowth originated from reports of increased eyelash growth in individuals treated with latanoprost for glaucoma.

Minoxidil11-13  

Topical minoxidil is a vasodilator that was originally developed as an oral antihypertensive medication. Hair growth effects were identified following reports of hypertrichosis in patients receiving oral minoxidil. As a result, topical minoxidil was later approved by the FDA for the treatment of androgenetic alopecia in both men and women.

Tretinoin14-18

Tretinoin is a naturally occurring derivative of vitamin A, also referred to as all-trans-retinoic acid. Retinoids are involved in the regulation of cell reproduction, proliferation, and differentiation. When combined with minoxidil, tretinoin has been associated with increased expression of specific markers related to hair growth, including Erk, Akt, Bcl-2, and Bax.

Finasteride1-3

Finasteride is an analog of testosterone that acts as a competitive, specific inhibitor of type II 5-alpha-reductase, an intracellular enzyme that converts testosterone to the potent androgen 5-alpha-dihydrotestosterone. The type II 5-alpha-reductase isozyme is primarily found in prostate, seminal vesicles, epididymides, and hair follicles, as well as liver. Dihydrotestosterone has been shown to increase prostate growth and can lead to hair thinning. Finasteride has been shown to shrink the prostate to improve urinary flow and in scalp lowers dihydrotestosterone to slow hair loss and promote regrowth.

Hydrocortisone4,5

The anti-inflammatory effects of topical hydrocortisone may occur through vasoconstriction. The vasoconstriction minimizes inflammatory mediators delivered to the inflamed area. Topical hydrocortisone may also inhibit the release of phospholipase A2, which reduces prostaglandins and leukotriene. Lastly, topical hydrocortisone inhibits DNA and transcription factors related to inflammation. It does this by increasing the expression of anti-inflammatory genes and indirectly inhibit inflammatory transcription factors, such as NF-kB, to decrease the expression of pro-inflammatory genes.

Topical hydrocortisone also has an anti-mitotic effect by decreasing epidermal mitosis mediated through an increase in lipocortin, an endogenous glucocorticoid-regulated protein.

Topical hydrocortisone also inhibits humoral factors in the inflammatory response by suppressing immune cells from maturing, differentiating and proliferating.

Latanoprost6-10

Latanoprost binds to the prostaglandin F2α receptor on hair follicle dermal papilla cells, influencing the hair growth cycle as follows:

  1. Prolongation of Anagen Phase (Growth Phase):

Increases the duration of anagen, which may result in longer and thicker hair shafts.

  1. Stimulation of Melanogenesis:

May enhance pigmentation in vellus hairs, which may make them appear darker and more terminal-like.

  1. Increased Follicular Density:

Some studies suggest latanoprost may increase the number of follicles actively producing hair, particularly in the eyelash and eyebrow regions, and potentially the scalp.

Minoxidil11-13

The drug has many mechanisms in supporting hair growth:

  • Potassium channel opening: Minoxidil is a K⁺-ATP channel opener, which may result in vasodilation and enhanced blood flow to hair follicles.
  • Prolongation of the hair cycle: It may extend the growth phase of the hair cycle, leading to increased follicle size and more robust hair shafts.
  • Activation of prostaglandins: May indirectly affect prostaglandin-mediated signaling to stimulate hair follicle activity.
  • Upregulation of vascular endothelial growth factor (VEGF): Promotes angiogenesis in dermal papillae, which may improve follicular nourishment.

Tretinoin14-18

Tretinoin may have several mechanisms to facilitate hair growth including the following:

  • Cell turnover-Tretinoin facilitates skin cell turnover which may open up hair follicles for hair growth
  • Enhanced absorption-Tretinoin may help absorption of minoxidil. This may be from the increased absorption of minoxidil which may be the result of increased sulfonation.
  • Prolonged anagen phase-Tretinoin may help lengthen the growth phase of hair follicles.

Finasteride1-3,18

Common

  • Scalp pruritus, burning sensation, irritation, contact dermatitis, and erythema

With systematic absorption (rare)

  • Decreased libido
  • Erectile dysfunction
  • Ejaculatory disorders (e.g., reduced volume)
  • Breast tenderness or enlargement
  • Gynecomastia

 

Hydrocortisone4

Common

  • Skin irritation, pruritus, dry skin, folliculitis, hair growth, acne

Latanoprost9,10

Common

  • Local irritation (itching, burning, erythema)
  • Hyperpigmentation of skin (especially around eyelids or eyebrows)
  • Increased pigmentation of treated hair
  • Eyelid darkening (rare with scalp use)
  • Unwanted hair growth if medication spreads to unintended areas
  • Eye irritation (if it migrates to eye area)

 

Minoxidil11-13

Common

Topical minoxidil is generally well tolerated but may cause local effects:

  • Scalp irritation, dryness, flaking
  • Erythema or contact dermatitis (more common with propylene glycol-containing formulations)
  • Pruritus or burning sensation
  • Unwanted facial hair growth (esp. in women or if solution drips onto other areas)

 

Tretinoin14

Common

  • Skin irritation, such as peeling, xerosis (dry skin), burning, stinging, erythema, and pruritus

Contraindications1-4,9,10-14,18

  • Known hypersensitivity or intolerance to finasteride, hydrocortisone, latanoprost, minoxidil, and tretinoin or excipients
  • Contraindicated in women who are or may become pregnant if absorbed systemically due to risk of teratogenicity (can cause abnormalities in the external genitalia of male fetuses)

Precautions1-4,9,10-14,18 

  • Do not apply to open wounds
  • Finasteride lowers serum PSA levels by ~50% after 6 months, which can mask early detection of prostate cancer.
  • Use cautiously in patients with hepatic dysfunction. The drug is metabolized extensively in the liver.

Store at room temperatures between (59-86°F). Protect from light and keep the container tightly closed. Women should not handle crushed or broken finasteride tablets when they are pregnant or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus. Keep out of reach of children and pets.

  1. Finasteride (Proscar) package insert. www.accessdata.fda.gov/drugsatfda_docs/label/2010/020180s037lbl.pdf October 10, 2010. Accessed August 15, 2025.
  2. Finasteride (Propecia) accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf April 2012. Accessed August 15, 2025.
  3. Clinical Pharmacology finasteride clinical monograph 2025 https://www.clinicalkey.com/pharmacology/  Accessed August 15, 2025
  4. Clinical Pharmacology hydrocortisone clinical monograph 2025 https://www.clinicalkey.com/pharmacology/    Accessed August 15, 2025
  5. Gabros S, Nessel TA. Topical Corticosteroids. April 26, 2025. Accessed July 27, 2025.
  6. Johnstone, M. A. (1997). Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in latanoprost therapy. American Journal of Ophthalmology, 120(7), 999–1001.
  7. Blume-Peytavi, U., et al. (2012). Latanoprost stimulates human scalp hair growth in vivo. Journal of the American Academy of Dermatology, 66(5), 807–814.
  8. Kwon, O. S., et al. (2007). Prostaglandin analogs as a potential treatment for hair loss: Latanoprost and bimatoprost in the management of alopecia. International Journal of Dermatology, 46(9), 1044–1048.
  9. Clinical Pharmacology. Elsevier. Latanoprost Monograph. Accessed August 15, 2025
  10. FDA Drug Label: Xalatan (latanoprost ophthalmic solution) https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a98595b3-9f47-48e0-b18d-550a2095f264&type=display Revised May 2023. Accessed June 15, 2025
  11. Clinical Pharmacology [Internet].: Elsevier; accessed May 2025; Minoxidil topical monograph. Available from: ClinicalKey; https://www.clinicalkey.com/pharmacology/monograph/408?n=Minoxidil
  12. Rogaine® (minoxidil topical solution) package insert. Johnson & Johnson Consumer Inc. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=12fd18f0-859c-7b9a-e063-6394a90addbf&type=display Revised March 2024. Accessed June 16, 2025
  13. Goren A, Naccarato T. Minoxidil in the treatment of androgenetic alopecia. Dermatol Ther. 2018 Sep;31(5):e12686.
  14. Clinical Pharmacology tretinoin clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
  15. Yoham AL, Casadesus D. Tretinoin. March 27, 2023. Accessed July 27, 2025.
  16. Sharma A, Goren A, Dhurat R, Agrawal S, Sinclair R, Trüeb RM, Vañó-Galván S, Chen G, Tan Y, Kovacevic M, Situm M, McCoy J. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatol Ther. 2019 May;32(3):e12915.
  17. Can Tretinoin Help with Hair Growth? https://cityskinclinic.com/tretinoin-hair-growth/ June 12, 2025. Accessed August 15, 2025
  18. Gupta AK, Talukder M. Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative? J Cosmet Dermatol. 2022 May;21(5):1841-1848.

WPPL operates as a 503A compounding pharmacy and prepares individualized prescription medications pursuant to provider direction. Compounded preparations are not reviewed, tested, or approved by the FDA.

This listing also includes commercially manufactured products for convenience; these items are not compounded by our pharmacy and are sold as provided by their manufacturers. Any statements regarding non-compounded products are manufacturer-supplied, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease. WPPL does not verify or endorse any therapeutic claims made by manufacturers. Please refer to original labeling for complete product information.

EXPLORE MORE

Related Medications

Licensed to ship across the U.S.

Your orders arrive promptly and privately, delivered directly to your door.

Providers: Let’s Partner for Better Patient Care

If you are a physician, clinic, or practice seeking a dependable Compounding Pharmacy partner, WP Pharma Labs is here to help. With dedicated account setup, streamlined ordering and responsive service, we support your therapeutic goals with specialized compounds designed for your patients.

To check product availability, check on the status of an existing order, request refills:
orders@wppharmalabs.com

New providers setup / update an existing account:
newaccounts@wppharmalabs.com